M118 – A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes

Summary

The initial choice of anticoagulant therapy administered in emergency departments for acute coronary syndromes (ACS) has important consequences for subsequent patient care, as neither unfractionated heparin (UFH) nor low-molecularweight heparin (LMWH) are ideally suited for all potential clinical treatment pathways. UFH remains widely used for surgical interventions because of the ability to rapidly reverse its anticoagulant activity. However, the unpredictable pharmacokinetic profile of UFH presents safety issues, and the low subcutaneous bioavailability limits the utility of UFH for patients who are medically managed. LMWH has superior pharmacokinetic properties, but its anticoagulant activity cannot be effectively monitored or reversed during surgery. There is an unmet medical need for a baseline anticoagulant therapy that addresses these shortcomings while retaining the beneficial properties of both UFH and LMWH. We describe here M118, a novel LMWH designed specifically for use in the treatment of ACS. M118 shows broad anticoagulant activity, including potent activity against both factor Xa (∼240 IU/mg) and thrombin (factor IIa; ∼170 IU/ mg), low polydispersity, high (78%) subcutaneous bioavailability in rabbits, and predictable subcutaneous and intravenous pharmacokinetics. Additionally, the anticoagulant activity of M118 is monitorable by standard coagulation assays and is reversible with protamine. M118 demonstrates superior activity to conventional LMWH in a rabbit model of abdominal arterial thrombosis without increasing bleeding risk, and is currently being evaluated in a phase II clinical trial evaluating efficacy and safety in patients undergoing percutaneous coronary intervention.

Keywords

Heparins - coagulation inhibitors - acute myocardial infarction - arterial thrombosis - thrombin

• References

• 1 Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-918.
• 2 Orbe J, Zudaire M, Serrano R. et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008; 99: 382-387.
• 3 Hoffman M, Monroe 3rd DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-965.
• 4 Gerotziafas GT, Petropoulou AD, Verdy E. et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 05: 955-962.
• 5 Danielsson A, Raub E, Lindahl U. et al. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261: 15467-15473.
• 6 Hirsh J, Raschke R. Heparin and low-molecularweight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (03) Suppl 188S-203S.
• 7 Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. Thromb Haemost 2008; 99: 807-818.
• 8 Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000; 26 (Suppl. 01) 31-38.
• 9 Cohen M, Hoekstra J. The use of adjunctive anticoagulants in patients with acute coronary syndrome transitioning to percutaneous coronary intervention. Am J Emerg Med 2008; 26: 932-941.
• 10 Gatt A, van Veen JJ, Woolley AM. et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-355.
• 11 White HD, Kleiman NS, Mahaffey KW. et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006; 152: 1042-1050.
• 12 Becker RC. Optimizing heparin compounds: a working construct for future antithrombotic drug development. J Thromb Thrombolysis 2004; 18: 55-58.
• 13 Linhardt RJ. Chemical and Enzymatic Methods for the Depolymerization and Modification of Heparin. In: Carbohydrates-Synthetic Methods and Applications in Medicinal Chemistry. Kodansha/VCH Publishers; Tokyo/Weinheim: 1992: 385-401.
• 14 Sundaram M, Qi Y, Shriver Z. et al. Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci USA 2003; 100: 651-656.
• 15 Samama MM, Le Flem L, Guinet C. et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007; 05: 2554-2556.
• 16 Volovyk Z, Monroe DM, Qi YW. et al. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin in a cell based model of thrombin generation. J Thromb Thrombolysis 2009; 28: 132-139.
• 17 Ferguson JJ, Califf RM, Antman EM. et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. J Am Med Assoc 2004; 292: 45-54.